GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tellgen Corp (SZSE:300642) » Definitions » Institutional Ownership

Tellgen (SZSE:300642) Institutional Ownership : 0.61% (As of May. 09, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Tellgen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tellgen's institutional ownership is 0.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tellgen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tellgen's Float Percentage Of Total Shares Outstanding is 0.00%.


Tellgen Institutional Ownership Historical Data

The historical data trend for Tellgen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tellgen Institutional Ownership Chart

Tellgen Historical Data

The historical data trend for Tellgen can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31 2025-04-30
Institutional Ownership 0.77 0.77 0.77 0.77 0.77 0.61 0.61 0.61 0.61 0.61

Tellgen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Tellgen Business Description

Traded in Other Exchanges
N/A
Address
No. 412 Huiqing Road, Pudong New District, Shanghai, CHN, 201201
Tellgen Corp manufactures and distributes in vitro diagnostic devices for detection of tumor. Its products include tumor marker, human papillomavirus, real time PCR, DNA methylation, autoimmune antibody, infectious disease and others. The company has developed products in the fields of tumor detection, cervical cancer screening, DNA methylation detection, male infertility and prenatal and postnatal care. Its products include tumor marker series products, human papillomavirus series products, Y chromosome microdeletion detection products, real time PCR, autoimmune antibody, and others.
Executives
Zhou Ai Guo Directors, executives
Chen Si Han Securities Affairs Representative

Tellgen Headlines

No Headlines